Veru to present late-breaker oral presentation of sabizabulin treatment for hospitalized adults with covid-19 on supplemental oxygen at infectious disease week 2022

Miami, oct. 13, 2022 (globe newswire) -- veru inc. (nasdaq: veru), a biopharmaceutical company focused on developing novel medicines for covid-19 and other viral ards-related diseases and for oncology, today announced that data from the phase 3 trial of sabizabulin for hospitalized moderate to severe covid-19 patients who required supplemental oxygen has been accepted as a late-breaker oral presentation at the upcoming idweek (infectious disease week) 2022 taking place october 19-23, 2022, in washington, d.c.
VERU Ratings Summary
VERU Quant Ranking